Iovance Biotherapeutics Net Income From Continuing Ops Over Time
| IOVA Stock | USD 2.53 0.17 7.20% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Iovance Biotherapeutics Performance and Iovance Biotherapeutics Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iovance Biotherapeutics. Market participants price Iovance higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Iovance Biotherapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (1.19) | Revenue Per Share | Quarterly Revenue Growth 0.152 | Return On Assets | Return On Equity |
Understanding Iovance Biotherapeutics requires distinguishing between market price and book value, where the latter reflects Iovance's accounting equity. The concept of intrinsic value - what Iovance Biotherapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Iovance Biotherapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Iovance Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iovance Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Iovance Biotherapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income From Continuing Ops Analysis
Compare Iovance Biotherapeutics and related stocks such as Ginkgo Bioworks Holdings, MBX Biosciences Common, and Erasca Inc Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DNA | (119.9 M) | (119.9 M) | (119.9 M) | (119.9 M) | (119.9 M) | (119.9 M) | (119.9 M) | (119.9 M) | (119.9 M) | (119.9 M) | (126.7 M) | (1.8 B) | (2.1 B) | (854.3 M) | (547 M) | (492.3 M) | (516.9 M) |
| MBX | (26.1 M) | (26.1 M) | (26.1 M) | (26.1 M) | (26.1 M) | (26.1 M) | (26.1 M) | (26.1 M) | (26.1 M) | (26.1 M) | (26.1 M) | (26.1 M) | (26.1 M) | (32.6 M) | (61.9 M) | (55.7 M) | (58.5 M) |
| ERAS | (12 M) | (12 M) | (12 M) | (12 M) | (12 M) | (12 M) | (12 M) | (12 M) | (12 M) | (12 M) | (101.7 M) | (122.8 M) | (242.8 M) | (230.6 M) | (161.7 M) | (145.5 M) | (152.8 M) |
| REPL | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (19.7 M) | (30.8 M) | (52.6 M) | (80.9 M) | (118 M) | (174.3 M) | (215.8 M) | (247.3 M) | (222.6 M) | (211.4 M) |
| MGTX | (19.8 M) | (19.8 M) | (19.8 M) | (19.8 M) | (19.8 M) | (19.8 M) | (19.8 M) | (31 M) | (82.9 M) | (54.7 M) | (58 M) | (79.6 M) | (130 M) | (131.6 M) | (147.8 M) | (133 M) | (126.4 M) |
| MLTX | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (50.1 M) | (52.7 M) | (121.2 M) | (109.1 M) | (103.7 M) |
| VIR | (69.9 M) | (69.9 M) | (69.9 M) | (69.9 M) | (69.9 M) | (69.9 M) | (69.9 M) | (69.9 M) | (115.9 M) | (174.7 M) | (298.7 M) | 528.6 M | 515.8 M | (600.7 M) | (522 M) | (469.8 M) | (446.3 M) |
| CTMX | (30.3 M) | (30.3 M) | (30.3 M) | (30.3 M) | (30.3 M) | (35.4 M) | (58.9 M) | (43.1 M) | (84.6 M) | (102.2 M) | (32.9 M) | (83.6 M) | (115.9 M) | (10.2 M) | 31.9 M | 36.6 M | 38.5 M |
| ATXS | (27.4 M) | (27.4 M) | (27.4 M) | (27.4 M) | (27.4 M) | (27.4 M) | (27.4 M) | (27.4 M) | (25.9 M) | (26.3 M) | (37.3 M) | (194.9 M) | (51.8 M) | (72.9 M) | (94.3 M) | (84.8 M) | (89.1 M) |
| AVBP | (36.9 M) | (36.9 M) | (36.9 M) | (36.9 M) | (36.9 M) | (36.9 M) | (36.9 M) | (36.9 M) | (36.9 M) | (36.9 M) | (36.9 M) | (36.9 M) | (69.3 M) | (80.5 M) | (80.5 M) | (72.4 M) | (76.1 M) |
Iovance Biotherapeutics and related stocks such as Ginkgo Bioworks Holdings, MBX Biosciences Common, and Erasca Inc Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Iovance Biotherapeutics | IOVA |
| Classification | Cancer Fighters |
| Business Address | 825 Industrial Road, |
| Exchange | NASDAQ Exchange |
USD 2.53
Check out Iovance Biotherapeutics Performance and Iovance Biotherapeutics Correlation. For information on how to trade Iovance Stock refer to our How to Trade Iovance Stock guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Iovance Biotherapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.